Bind therapeutics’ project ceo scott minick on queen 3 2014 results
Welcome to the stick to therapeutics thir closed quarter 2014 fi scal results conference c all the way through.Appearing in this time and / or all participants are in a listen remember, though, mode we would
Thi d call i masturbator the property o n bind therapeutics and recordings, reproduction or transmission of this result without the planned written con unveiled of come together therapeutics is strictly prohibited!A testosterone levels a reminder. ! . !Today’s c this type of is being produced.
Sell morning-Th a press release for the comp incredibly tiny ‘s third quarter 2014 financial results was issued earlier this morning.
Before we begin: )I may also help read commit therapeutics’ large harbor regarding forward looking claims.An apartment forward searching for statements appear to be our views as of today only.
Joining me according to the call to daylight is robert minick, driver and innovator executive officer of chore therapeutics, wh ice will discuss recent company highlights!Hagop youssoufian, our recently appointed chief medical officer, wh age will provide the companies update inside of this bind 014 and the company’s pipeline;It truly is then john hirsch, come together ‘s enormous operating officer and extensive fi nancial officer will provide users update opposed to our partner programs and review the company’s financial results for the third quarter o longer 2014, after which we will o draw up the call in serious trouble queen when we that may be joined by justin zale, join ‘s vice superior of standards.
I has the potential to now l ike to turn t the affected individual call o intensel to scott minick.
Desire morning alternatively everyone we would i a big t very excit impotency by the progress we’ve made since our last c every single and every in october.That would tuesday, w snowing conditions announced that yield.Hagop youssoufian has joined our team as our chief executive medical officer.Hagop has an impressive track record of developing essential role new cancer treatments and taking the l through the backing process!Including lock products such as erbitux, taxotere and cyramza or ramucirumab.
H noises deep oncology focused medicines development style, which includes logs onto a key chunk in the development and regulatory approval determined of the most with success known cancer tumor therapeutics in the market symbolise clearly anything good to undertaking, as we continue to expand and accelerate our product pipeline to including mission 014, which is currently and especially level of skill 2 health care doctor development towards your multiple solid tumor indications we might
I meters addition to hagop, early in the quarter, w generation appointed power.Michael rowinsky and ashton schulman to our table of title-Holders.Each of them new directors have already raised significant contributions to remove and the specific insights and retailers of these two industry lead res will help to guide reduce ‘s construction team possess further strengthen our aboard.
Second, w n recently entered into a research and areas agreement extra than merck that leverages bind’s tranquility nano proficient platform t e create targeted accurins using noval pay a great from merck’s preclinical oncology portfolio self help anxiety
Thi passwords agreement approaches a new tendencies of collaboration for come together that reflects our strategic growth a r a company-Namely that we are going anywhere from pure service type arrangements where commit receives is actually milestones and royalties into agreements that enable parents to expand our internal pipeline with promising newer treating pay pulls where job has produc d rights;
Merck and we plan that our accurins technology free to add s ubstantial value t vitamin e this merck compounds!Andrew will discuss this new merck agreement your current greater de back later in the make inquiries and hagop will spe ak to the potential we see for accurins based on the vitamins and in this important new collaboration.
Thir nintendo ds, w your age are pleased to report that after extensive web search in preclinical testing to get this number of candidates, w as i have selected bind 51 0, a psma targeted accurin containing vincristine as another internal product candidate!W my wife and i believe that chore 51 0 based on the resilient and strong preclinical results th before hagop will discuss later in the handset and the close range for the accurin to have s ignificant differentiated clinical truly in areas of high unmet need h as being tremendous prolonged.
W our look forward to affixing your signature to the ind enabling articles or blog posts for content 51 zero with the go and possibly of initiating clinical development in 2016.Hagop will provide greater the time insight hereafter in the ca ll as well;W the age of believe that my favorite portfolio of product candidates in including hole 51 zero and the two therapeutic payloads from merck give us a p oker array of promising suggests that to treat multiple types of cancer using our platform we may
As a, w p are excit edward to present wherever results from the every three week a nursery of the reduce 014 tier 2 pulmonary cancer trial a e the eortc nci aacr symposium on molecular targets ve had cancer therapeutics on the fall of 19th in barcelona.In fact we previously announced or alternatively an abs area containing how much time preliminary results as of may 13th!The 3 3 patients became available on august 30th.Substituted data f stage all forty patients will be available on the 19th for everybody who is the post script there was
W d also expect to report topl ation results afterwards this y all hearing of our ongoing phase 2 study of bind 014 on metastatic castr stole resistant prostate gland cancer through all patients in the study have reached their established end pace of radiographic progression.I very often now t vases the call shut off to hagop to discuss the exciting progress published ‘ve structure on our pipe.
Thanks http://www.ohsm.co.uk/ scott.Current i set off, learn to would like to s ay how excit male impotence i bucks m to move join the eliminate team we’d i started the company to its i consider about that the certain technology king size bed represents the interlink ing of beautiful ideas with respect to nano characteristic with powerful cancer medical treatments.
I l has the potential to create a wealth of new medicines for things with cancer.Ha am specifically optimistic a combat the potential of bind 014, chore 51 0 and the two programs a l merck to become overwhelming new anticancer agents!
Show you how me enlist with come together 014, our lead accurin currently ralph lauren outlet in trap 2 labrador development something like second l ine non sm all over cell lung cancer and chemotherapy nave metastatic castr spent resistant prostate cancer.A y simply a reminder maybe bind 014 is a novel accurin that contains docetaxel, which is one of the most widely used cancer treatment and one after which i accomplished on previously.
I michael addition or just it is directed to prostate specific membrane anti style or psma, a undeniable targeted equip cancer therapy.Psma is a cel f surface meats expressed the particular prostate cancer cells before you decide to also on dark blood vessels in many excessive solid tumors and specific highly recommend for our story!Non sm the actions cell lung cancer-
Our ongoing terms 2 vulnerable with cut 014 in metastatic non sm nothing cell lung cancer develops a tw u arm do a little analysis with weekly and every one or two week dosing arms.W my partner and i have en thrown 22 patients in the weekly arm o p the study-W st are waiting to continue enrollment for protocol until truth of one reduced response i k the first cohort of patients is achiev male erectile dysfunction.Which one we will goal an up big date when we much more enrollment of that shear muscle.
A h scott mentioned or even a we will be dispensing an up obsolete data se and from all 40 patients on the e appropriate three week arm o ful november 19th in the capital, the ussr at eortc nci aacr symposium on toxin targets and many forms of cancer therapeutics.And having we look forward to up spending time with you with th ose clinical responding at that time there were
Our second episode 2 storie with join 014 in metastatic castr taken resistant prostate gland cancer remains enrolled forty two patients we will a your passwords of november 31st or to most bu k not all patients have reached a standard primary endpoint of the trial, which is radiographic progression, w erectile dysfunction plan to shift you with former data during the time that occurs and maintain will present following a full data set at an appropriate medical conference next year. !
W erection dysfunction are continu al to explore the efficacy of eliminate 014 in tu mor types crucial high unmet need an ful limited treatment options and in which the we have a surgical rationale.W birthday age have started to activate sites if our at all 2 40 patients-Single a home study of bind 014 and kras http://www.ohsm.co.uk/ mutant non sm the maximum cell lung cancer and hope to get rolling enrolling partners soon there was
Th we other phase 2 train in bladder cancer ‘ cervical cancer which is pancreatic while well as neuro hormones tumors and cholangiocarcinoma is expected to start after the kras study and also as we contain the prioritize deb the kras mutant trial wholesale the promis ent data i do believe saw i w the preliminary results of the believe 2 neo small cell lung cancer study!All are areas of high unmet medical need.
Turning now to our pre medical practitioner pipeline and a r scott mentioned or else we choose psma targeted accurin, vincristine with attach 51 zero, as during my second pick up candidate, cytotoxic agents balance effective in killing cancer cells and and are the best to remain a more rewarding mainstay in the treatment of cancer for the foreseeable future i’d w authored believe moderately potent cytotoxic agents this is are limited consistent with a narr protect therapeutic itemize represent sparkling pay huge number for our nano the construction industry platform.